Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001389963 | SCV001591525 | pathogenic | Arrhythmogenic right ventricular dysplasia 9 | 2023-12-15 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln393*) in the PKP2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PKP2 are known to be pathogenic (PMID: 15489853, 23911551). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of arrhythmogenic right ventricular cardiomyopathy (PMID: 23812740, 27532257). ClinVar contains an entry for this variant (Variation ID: 188658). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV001778768 | SCV002015761 | likely pathogenic | not provided | 2021-11-05 | criteria provided, single submitter | clinical testing | Reported in association with arrhythmogenic right ventricular cardiomyopathy (ARVC) (Baskin et al., 2013; Walsh et al., 2017); Not observed at significant frequency in large population cohorts (Lek et al., 2016); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 27532257, 23812740, 31402444, 26582918) |
Ambry Genetics | RCV002326930 | SCV002637582 | pathogenic | Cardiovascular phenotype | 2019-08-30 | criteria provided, single submitter | clinical testing | The p.Q393* pathogenic mutation (also known as c.1177C>T), located in coding exon 5 of the PKP2 gene, results from a C to T substitution at nucleotide position 1177. This changes the amino acid from a glutamine to a stop codon within coding exon 5. This alteration has been reported in association with arrhythmogenic right ventricular cardiomyopathy (ARVC) (Baskin B et al. Hum. Genet., 2013 Nov;132:1245-52; Walsh R et al. Genet. Med., 2017 02;19:192-203). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |